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Background: Pneumococcal meningitis is the most common and severe form of bacterial meningitis. Fatality rates are
substantial, and long-term sequelae develop in about half of survivors. Disease outcome has been related to the severity
of the pro-inflammatory response in the subarachnoid space. The complement system, which mediates key inflammatory
processes, has been implicated as a modulator of pneumococcal meningitis disease severity in animal studies.
Methods: We investigated mannose-binding lectin-associated serine protease (MASP-2) levels in cerebrospinal fluid (CSF)
samples derived from the diagnostic lumbar puncture, which was available for 307 of 792 pneumococcal meningitis
episodes included in our prospective nationwide cohort study (39%), and the association between these levels and
clinical outcome. Subsequently, we studied the role of MASP-2 in our experimental pneumococcal meningitis mouse
model using Masp2−/− mice and evaluated the potential of adjuvant treatment with MASP-2-specific monoclonal
antibodies in wild-type (WT) mice.
Results: MASP-2 levels in cerebrospinal fluid of patients with bacterial meningitis were correlated with poor functional
outcome. Consistent with these human data, Masp2-deficient mice with pneumococcal meningitis had lower cytokine
levels and increased survival compared to WT mice. Adjuvant treatment with MASP-2-specific monoclonal antibodies led
to reduced complement activation and decreased disease severity.
Conclusions: MASP-2 contributes to poor disease outcome in human and mice with pneumococcal meningitis. MASP-2-
specific monoclonal antibodies can be used to attenuate the inflammatory response in pneumococcal meningitis.Background
Acute community-acquired bacterial meningitis is a life-
threatening disease associated with substantial morbidity
and mortality and ranks among the top ten infectious
causes of death [1]. Streptococcus pneumoniae is the most
common cause of bacterial meningitis in adults account-
ing for 50–70% of cases in developed countries [2, 3].
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as hearing loss, focal deficits, and motor and cognitive
impairments significantly affect the quality of life of survi-
vors [2, 4–6]. Predisposing factors for pneumococcal men-
ingitis include pneumonia, otitis, sinusitis, cerebrospinal
fluid (CSF) leaks, splenectomy or asplenic states, and pri-
mary or acquired immune deficiencies [3, 5]. Genetic
studies of extreme phenotypes have revealed that patients
with single-gene inborn errors in MyD88, IRAK4, and
NEMO affecting the activation of the canonical Toll-like
receptor (TLR) and interleukin (IL)-1R signaling pathways
or in complement components are susceptible for invasive
pneumococcal disease [7–10].
Experimental studies in pneumococcal meningitis
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host inflammatory response is activated by recognition
of pathogen-associated molecular patterns by the in-
nate immune system, e.g., by Toll-like receptors and
inflammasomes [11]. Subsequently, the complement
system is activated, leading to massive release of
anaphylotoxins and chemotaxis and activation of neu-
trophils [11]. Genetic variants in complement system,
TLR and IL-1R signaling pathways, and the M-TOR
pathway have been identified to be associated with
outcome in pneumococcal meningitis [7, 9, 12–15].
Inhibition of the final common pathway in the com-
plement cascade has been identified as target for
adjunctive treatment for experimental pneumococcal
meningitis. Complement component 5 (C5) inhibition
was shown to reduce inflammation of the central
nervous system and improve outcome [13, 16]. C5 in-
hibition shuts down the terminal complement effector
pathway but does not prevent the release of anaphyla-
toxin C3a and other upstream complement activation
events. Therefore, inhibition of the upstream activa-
tion pathways of the complement system may result in
a more complete reduction of complement-mediated
inflammation.
The classical pathway was initially proposed as the pre-
dominant pathway responsible for complement activation
during pneumococcal infection [17]. C1q-deficient mice
in which the classical pathway is disrupted and factor B-
deficient mice with a defective alternative pathway were
both more susceptible to intranasal and intraperitoneal
pneumococcal infection compared to wild-type mice.
Mice deficient in complement factor 3, affecting all path-
ways of complement activation, had increased susceptibil-
ity to invasive pneumococcal infection, as compared to
C1q, factor B, and C1q/FactorB knockouts, suggesting an
additional and important role of the lectin pathway in
pneumococcal infection [17]. This was confirmed by a
study in Masp2-deficient mice that showed increased
susceptibility to intranasal pneumococcal infection due to
decreased opsonization of S. pneumoniae [18]. Masp2-de-
ficient mice had similar survival times and mortality rates
compared to those previously reported in C1q-deficient
mice [18].
Thus, an intact complement system protects against
contraction of pneumococcal infection; however, in view
of the detrimental role of inflammation in disease progres-
sion, inhibition of mannose-binding lectin-associated
serine protease (MASP-2) presents to be an interesting tar-
get for complement blockade aiming to decrease inflam-
mation in pneumococcal meningitis. We studied multiple
aspects of the role of MASP-2 in pneumococcal meningi-
tis. First, we measured MASP-2 in CSF of pneumococcal
meningitis patients. Subsequently, we analyzed the role of
MASP-2 during experimental meningitis in our validatedpneumococcal meningitis mouse model using Masp2
knockout mice. Finally, we studied whether treatment with
MASP-2 antibodies improved outcome in a randomized
controlled investigator-blinded mouse experiment.
Methods
Dutch bacterial meningitis cohort
In a nationwide prospective cohort study, we included
adults with community-acquired bacterial meningitis
with positive CSF cultures who were identified by the
Netherlands Reference Laboratory for Bacterial Men-
ingitis (NRLBM). Methods have been described in de-
tail previously [19]. The NRLBM provided the names
of the hospitals where patients with bacterial meningi-
tis had been admitted 2 to 6 days previously. The
treating physician was contacted, and informed con-
sent was obtained from all participating patients or
their legally authorized representatives. Outcome was
graded at discharge according to the Glasgow Out-
come Scale (GOS), a well-validated instrument [20]. A
score of 1 indicates death; a score of 2 indicates a
vegetative state; a score of 3 indicates severe disability;
a score of 4 indicates moderate disability; and a score
of 5 indicates mild or no disability. A favorable out-
come was defined as a score of 5 and unfavorable out-
come as a score of 1 to 4. The study was approved by
the medical ethical committee of the Academic Med-
ical Centre, Amsterdam, the Netherlands.
CSF measurements
To evaluate whether MASP-2 CSF levels were increased
in CSF during pneumococcal meningitis and whether the
concentration was related to severity of disease and out-
come, we measured MASP-2 CSF levels in patients and
controls. CSF of patients was obtained from the diagnostic
lumbar puncture. Control samples were derived from left-
over CSF of patients with acute headache in whom a lum-
bar puncture was performed to exclude a subarachnoid
hemorrhage. These control CSF samples all had normal
leukocyte count and protein and glucose levels; the final
diagnosis in these patients was benign thunderclap head-
ache. CSF was centrifuged and the supernatant was stored
at −80 °C until assayed. MASP-2, C5a, and C5b-9 levels
were determined using commercially available ELISA kits
(MyBioSource and Microvue Quidel, respectively) accord-
ing to manufacturer instructions.
Pneumococcal meningitis mouse model
To further determine the role of MASP-2 during pneumo-
coccal meningitis and evaluate whether blocking MASP-2
could be used to improve outcome, we used our well-
validated pneumococcal meningitis mouse model [21].
In this model, C57BL/6NCrl mice (Charles River Labora-
tories, Germany), aged 8–12 weeks old, were weighed and
Kasanmoentalib et al. Journal of Neuroinflammation  (2017) 14:2 Page 3 of 10clinically examined prior to infection. Bacterial meningitis
was induced by intracisternal injection of 1 μl of 107 CFU/
ml S. pneumoniae serotype 3 (ATCC 6303; American
Type Culture Collection, Rockville, MD, USA) under
short-term isoflurane anesthesia. Controls were injected
with 1 μl sterile saline. All animals were clinically exam-
ined and scored directly following inoculation and at regu-
lar intervals. Clinical scoring consisted of weight loss,
activity, time to return to upright position, state of fur,
posture, eye discharge or protrusion, respiration rate, ir-
regular/labored breathing, epilepsy, limb paresis, and co-
ordination. In healthy mice, the score was 0, and mice
with a score of 15 or more were critically ill and therefore
euthanized. Other humane endpoints were >25% weight
loss, ≥2 seizures per 15 min, status epilepticus, and hemi-
paralysis. Mice were euthanized by intraperitoneal injec-
tion of ketamine (190 mg/kg, Eurovet Animal Health,
Bladel, the Netherlands) in combination with dexmedeto-
midine (0.3 mg/kg, Pfizer Animal Health, Capelle aan den
IJssel, the Netherlands). After, euthanasia blood was
collected by transcardial puncture and citrated in a 1:4
citrate to blood ratio. CSF was collected by puncture of
the cisterna magna and diluted 1:100 in sterile saline.
Subsequently, mice were perfused with sterile phosphate-
buffered saline and the brain, spleen, and lung were
harvested. The right hemisphere was snap frozen in liquid
nitrogen, and the left hemisphere, spleen, and lung were
taken up in 20% weight per volume sterile saline and ho-
mogenized with a tissue homogenizer. Bacterial titers were
determined by plating serial tenfold dilutions of blood,
CSF, brain, spleen, and lung homogenates on sheep-blood
agar plates and incubating for 16 h at 37 °C. Citrated
blood was centrifuged at 2000 rpm for 15 min at 4 °C. Tis-
sue homogenates were lysed as described before [21].
Plasma, CSF, and lysed supernatant were stored at −20 °C
until assayed. Experiments were approved by the Institu-
tional Animal Care and Use Committee of the Academic
Medical Center, Amsterdam, the Netherlands.
MASP-2 expression experiments
To evaluate the expression profile of MASP-2, pneumo-
coccal meningitis was induced and mice were sacrificed at
6 h (n = 5), 24 h (n = 5), and 48 h (n = 5) after infection.
Mice inoculated with sterile saline and sacrificed at 24 h
(n = 5) served as control. Mice in the 48 h group were
treated intraperitoneal with ceftriaxone (100 mg/kg) at
20 h after infection.
Masp2 deficiency experiments
To evaluate the effect of Masp2 deficiency on disease se-
verity and mortality, C57BL/6NCrl wild-type (WT) mice
(n = 12) and Masp2-deficient mice with a C57/BL6N
background (Masp2−/−, Omeros Corp., n = 12) were in-
fected and observed for 60 h in a survival experiment.Mice deficient in Masp2 have been described elsewhere
[22]. In a time point experiment, mice were euthanized
at 6 (WT infected n = 12, Masp2−/− infected n = 12) and
30 (WT infected n = 12, Masp2−/− infected n = 12, WT
control n = 6, Masp2−/− control n = 6) h after infection.
Adjuvant treatment with MASP-2 antibodies
The previously described recombinant monoclonal
antibody AbD04211 inhibits mouse MASP-2 and is able
to block lectin pathway activity for 7 days when given
intraperitoneally in a single dose of 0.6 mg/kg [22]. To
assess the effect of adjuvant treatment with this anti-
body against MASP-2 on disease severity and mortality,
a survival study was performed. WT mice were infected
and treated intraperitoneally at 20 h after infection with
ceftriaxone (100 mg/kg) in combination with adjuvant
treatment and observed for 68 h. Adjuvant treatment
consisted of sterile saline (n = 24), isotype antibodies
(MAB205P, 1 mg/kg, n = 24), or MASP-2 antibodies
(AbD04211, 1 mg/kg, n = 24). When the sample size in
each group is 24, a 0.05 level two-sided log-rank test for
equality of survival curves will have 80% power to detect a
decrease in mortality from 45 and 10%. In a second
experiment, mice were treated with adjuvant sterile saline
(n = 18) or MASP-2 antibodies (AbD04211, 7 mg/kg, n =
18) and euthanized at 24 and 48 h after infection.
Protein expression
IL-1β, IL-6, IL-10, keratinocyte chemoattractant (KC),
tumor necrosis factor (TNF)-α, and macrophage inflamma-
tory protein (MIP)-2 levels were determined in mouse
plasma and brain homogenates with Luminex® technology
(Bio-Rad Laboratories). Expression of MASP-2 and C5b-9
was measured in mouse brain homogenates by ELISA
(CUSABIO and USCN Life Science, respectively). Albumin
concentrations in brain homogenates were determined with
ELISA (ALPCO Diagnostics).
Statistics
Continuous variables were compared using the Mann-
Whitney U test, and dichotomous variables were com-
pared using the chi-squared test. Survival was analyzed
using a log-rank test. Clinical scores were compared using
linear mixed models with group/treatment, time, and their
interaction as effects. For all models, a random slope was
modeled and estimates were corrected for autocorrelation
and/or unequal variances where appropriate. For all ana-
lyses, a P value <0.05 was regarded as significant.
Results
Cerebrospinal fluid levels of MASP-2 in patients with
pneumococcal meningitis
In our nationwide prospective cohort study, 792 episodes
of community-acquired pneumococcal meningitis were
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gated MASP-2 levels in cerebrospinal fluid (CSF) samples
derived from the diagnostic lumbar puncture, which
was available for 307 of 792 pneumococcal meningitis
episodes (39%). Baseline characteristics were similar in
patients with and without CSF available (Table 1). We
also measured MASP-2 CSF concentrations in 24
controls consisting of patients diagnosed with thunder-
clap headache in whom lumbar puncture was per-
formed to exclude subarachnoid headache. All controlsTable 1 Clinical characteristics of 792 pneumococcal meningitis pat
Characteristics Patients with CSF (n =
Age (year) 62 (51–70)
Male 142/307 (46)
Duration of symptoms <24 h 140/297 (47)
Predisposing conditions 202/307 (66)
Otitis or sinusitis 121/306 (40)
Pneumonia 28/298 (9)
Immunocompromised 96/307 (31)
Symptoms and signs on presentation a
Headache 221/267 (83)
Neck stiffness 224/297 (75)
Systolic blood pressure (mmHg) 148 (130–169)
Heart rate (bpm) 100 (86–112)
Body temperature (°C) 39.0 (38.2–39.7)
Score on Glascow Coma Scale 10 (8–13)b
<8 indicating coma 40/306 (13)
Focal neurologic deficits 90/306 (29)
Indexes of CSF inflammation c
Opening pressure 37 (27–43)
White blood cell count (/mm3) 2560 (460–6667)
White blood cell count <1000/mm3 103/295 (35)
Protein (g/l) 4.1 (2.5–6.0)
CSF blood glucose ratio 0.02 (0.00–0.23)
Positive blood culture 215/267 (81)
Score on Glasgow Outcome Scale
1—death 43/307 (14)
2—vegetative state 0/307 (0)
3—severe disability 14/307 (5)
4—moderate disability 64/307 (21)
5—good recovery 186/307 (61)
Data are number/number evaluated (percentage), and continuous data are mean ±
aSystolic blood pressure was evaluated in 301 patients, heart rate was evaluated in
bScore on Glasgow Coma Scale was evaluated in 306 patients
cCSF opening pressure was evaluated in 76 patients, CSF white blood cell count wa
CSF blood glucose ratio was evaluated in 288 patients
dSystolic blood pressure was evaluated in 477 patients, heart rate was evaluated in
eScore on Glasgow Coma Scale was evaluated in 483 patients
fCSF opening pressure was evaluated in 89 patients, CSF white blood cell count wa
blood glucose ratio was evaluated in 456 patientshad normal CSF leukocyte count and glucose and pro-
tein levels. We found that pneumococcal meningitis pa-
tients had increased levels of MASP-2 in their CSF
compared to controls (median 4.77 vs. 1.19 ng/ml, P <
0.0001). The CSF MASP-2 concentration was signifi-
cantly higher in patients with an unfavorable outcome,
defined as a score of 1 through 4 on the Glasgow Out-
come Scale (GOS) [20] compared to patients with a fa-
vorable outcome (5.39 vs. 4.36 ng/ml, P = 0.004; Fig. 1).
CSF MASP-2 concentration was higher in deceasedients with and without CSF available






























298 patients, and temperature was evaluated in 304 patients
s evaluated in 295 patients, CSF protein was evaluated in 293 patients, and
472 patients, and temperature was evaluated in 478 patients
s evaluated in 464 patients, CSF protein was evaluated in 464 patients, and CSF
Fig. 1 Cerebrospinal fluid MASP-2 concentration and outcome in
patients with pneumococcal meningitis. The MASP-2 concentration
was significantly higher in patients with an unfavorable outcome
(n = 121) compared to that in patients with a favorable outcome
(n = 186). Each dot represents an individual patient, lines represent
median values, and error bars are interquartile ranges. P value was
determined with the Mann-Whitney U test
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reach statistical significance (5.52 vs. 4.71 ng/ml, P = 0.090).
In patients with pneumococcal meningitis, CSF levels of
MASP-2 were positively correlated to C5a (ρ = 0.481, P <
0.0001), C5b-9 (ρ = 0.560, P < 0.0001) and the CSF protein
concentration (ρ = 0.488, P < 0.0001), but not to CSF
leukocyte count (ρ = 0.088, P = 0.130). Genetic variations in
the MASP-2 gene in patients with pneumococcal meningi-
tis did not influence disease severity (Additional file 1).
MASP-2 expression in experimental pneumococcal
meningitis
To study whether MASP-2 was expressed in our pneumo-
coccal meningitis mouse model [21], WT mice were
injected into the cisterna magna with S. pneumoniae sero-
type 3 (ATCC 6303; n = 15) or sterile saline (n = 5) and
sacrificed at 6, 24, or 48 h (n = 5 per time point). One
mouse reached a humane endpoint before the 48 h time
point, and MASP-2 concentrations were determined in
brain homogenates of the remaining 19 mice. Mice with
pneumococcal meningitis showed increased levels of
MASP-2 in brain at 6 (median 2.76 μg/mg tissue, P =
0.008) and 24 (median 3.01 μg/mg tissue, P = 0.008) h after
infection compared to saline-inoculated mice at 24 h after
inoculation (median 1.43 μg/mg tissue), but no difference
was observed after 48 h (median 1.31 μg/mg tissue).
Masp2 deficiency in experimental pneumococcal
meningitis
To investigate the role of MASP-2 in disease progression
in pneumococcal meningitis, we infected Masp2−/− (n =
12) and WT (n = 12) mice by intracisternal inoculation
with S. pneumoniae serotype 3 (ATCC 6303) [21]. At 20 hafter infection, all mice showed signs of illness, and the first
animals reached a humane endpoint at 32 h after infection.
All mice reached an endpoint during the 60-h observation
period. Masp2−/− mice had a significantly longer survival
time compared to WT mice (median survival 44 vs. 36 h,
log-rank P = 0.005; Fig. 2a). Clinical severity scores for
Masp2-deficient mice increased slower as compared to
those for WT mice (0.35 vs. 0.42 points/h, P = 0.013).
Next, we infected Masp2−/− (n = 24) and WT (n = 24)
mice by intracisternal inoculation with S. pneumoniae
and euthanized them at 6 and 30 h after infection. Mice
inoculated with sterile saline and euthanized at 30 h
served as control (Masp2−/− n = 6 and WT n = 6). One
WT mice with pneumococcal meningitis reached an
endpoint before the 30-h time point. Bacterial outgrowth
in CSF, blood, brain, spleen, and lung was similar be-
tween Masp2−/− and WT mice at 6 and 30 h after infec-
tion (Additional file 1: Figure S1). Masp2−/− mice had
significantly lower brain levels of interleukin (IL)-1β
(median 3.46 vs. 5.33 ng/mg tissue, P = 0.045), IL-10
(1.04 vs. 1.70 ng/mg tissue, P = 0.038), and TNF-α (9.32
vs. 22.58 ng/mg tissue, P = 0.025) compared to WT mice
at 30 h after infection (Fig. 2b–d). No differences were
observed between Masp2−/− and WT mice in brain IL-6,
KC, and MIP-2 levels or plasma levels of IL-1β, IL-6, IL-
10, KC, TNF-α, and MIP-2. Complement activation, as
indicated by brain levels of C5b-9, was also similar be-
tween Masp2−/− and WT mice 30 h post-infection (P =
0.88; Fig. 2e). During bacterial meningitis, destruction of
the blood-brain barrier is related to disease progression
and is reflected by increased brain albumin levels [11].
Brain albumin content was elevated in Masp2−/− (312.23
vs. 86.27 μg/mg tissue, P = 0.006) and WT (262.21 vs.
42.85 μg/mg tissue, P < 0.001) mice at 30 h after infection
compared to saline-inoculated mice. No differences were
observed between Masp2−/− and WT mice at 6 (P = 0.80)
and 30 (P = 0.74) h post-infection.
Adjuvant treatment with MASP-2 antibodies
We compared the effect of inhibitory MASP-2 anti-
bodies with saline in our treatment model. Thirty-six
WT mice were infected intracisternally with S. pneumo-
niae serotype 3 (ATCC 6303). At 20 h post-infection, all
mice were treated with ceftriaxone intraperitoneally plus
either MASP-2 antibodies (n = 18) or saline (n = 18)
and euthanized at 24 and 48 h. MASP-2 antibody-
treated mice had reduced brain levels of C5b-9 com-
pared to saline-treated mice at 24 h (median 1.08 vs.
2.53 μg/mg tissue, P = 0.017) and 48 h (0.85 vs. 1.25 μg/
mg tissue, P = 0.052) after infection. Plasma C5b-9
levels were reduced in MASP-2 antibody-treated mice
compared to saline-treated mice at 24 h after infection
(0.42 vs. 0.63 μg/ml, P = 0.022). MASP-2 antibody treat-
ment was associated with lower plasma levels of TNF-α
Fig. 2 Functional role of MASP-2 in pneumococcal meningitis mouse model. Kaplan-Meier curve showing increased survival in Masp2−/− mice
during pneumococcal meningitis (a). Cytokines and complement levels were measured in brain. Masp2−/− mice had significantly lower brain
levels of IL-1β, IL-10, and TNF-α 30 h after infection (b–d). Brain levels of C5b-9 were similar between Masp2−/− and WT mice (e). Data are given
as medians and 75th quartile; P values were determined with the Mann-Whitney U test
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vs. 0.25 ng/ml, P = 0.044). No differences were observed
in bacterial CFUs (Additional file 1: Figure S2), brain
levels of IL-1β, IL-6, IL-10, KC, TNF-α, and MIP-2, andplasma levels of IL-1β, IL-6, IL-10, KC, and MIP-2
between MASP-2 antibody- and saline-treated mice.
Next, we evaluated the effect of adjuvant treatment with
the MASP-2 antibodies on clinical severity and survival.
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three mice showed a limb paresis directly following inocu-
lation, and two mice reached a humane endpoint before
treatment was given and were excluded from the experi-
ment. The remaining 67 mice all showed signs of infection
20 h post-infection and were randomized for antibiotic
therapy consisting of ceftriaxone intraperitoneally in
combination with either saline (n = 22), isotype antibodies
(n = 23), or MASP-2 antibodies (n = 22). The 68-h mortal-
ity rates were 8 of 22 (36%) in the saline group, 7 of 23
(30%) in the isotype antibody group, and 3 of 22 (14%) in
the MASP-2 antibody group (Fig. 3a; Fisher’s exact test for
overall difference P = 0.21). Mortality in the MASP-2
antibody-treated group was lower compared to sham
treatment, but this did not reach statistical significance
(MASP-2 Ab vs. saline P = 0.088; MASP-2 Ab vs. isotype
antibody P = 0.210). Clinical severity scores for MASP-2
antibody-treated mice increased significantly slower as
compared to saline (Fig. 3b; 0.017 vs. 0.103 points/h, P =
0.002) and isotype antibody-treated mice (0.0017 vs. 0.080
points/h, P = 0.019).a
b
Fig. 3 The effect of adjuvant treatment with the MASP-2 antibodies on clin
Kaplan-Meier curve of WT mice with pneumococcal meningitis treated intr
combination with adjuvant treatment and observed for 68 h (a). Adjuvant
1 mg/kg), or MASP-2 antibodies (D04211, 1 mg/kg). There was no differenc
log-rank test. Clinical severity scores for MASP-2 antibody-treated mice incr
isotype antibody (0.0017 vs. 0.080 points/h)-treated mice (b). P values were
and their interaction as effectsDiscussion
Our results show that MASP-2 contributes to severity
and outcome in pneumococcal meningitis. In patients
with pneumococcal meningitis, MASP-2 concentration
was elevated in the CSF and high levels were associated
with poor functional outcome. In experimental pneumo-
coccal meningitis, Masp2 deficiency led to decreased
disease severity through decreased brain inflammation.
Adjuvant treatment with MASP-2-specific monoclonal
antibodies led to a decreased level of complement acti-
vation and disease severity.
The identified role of MASP-2 is consistent with the
two-edged sword theory on complement activation in
infectious disease [23]. A less readily activated comple-
ment system leads to increased susceptibility to infection
but reduced severity of inflammation, which is the key
pathogenic mechanism in pneumococcal meningitis. A
more readily activated complement system reduces the
risk of infection, but results in a poor prognosis in
bacterial meningitis [13, 24]. Masp2 deficiency was
previously shown to increase the risk of infection but weical severity and survival in experimental pneumococcal meningitis.
aperitoneally 20 h after infection with ceftriaxone (100 mg/kg) in
treatment consisted of sterile saline, isotype antibodies (MAB205P,
e in survival between groups. P values were determined with the
eased slower as compared to saline- (0.017 vs. 0.103 points/h) and
determined using linear mixed models with group/treatment, time,
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during meningitis, thereby improving survival.
Previous studies in pneumococcal infection showed
increased disease severity among Masp2-deficient and
MASP-2 antibody-treated mice, which was mainly driven
by decreased opsonization of bacteria, leading to increased
bacterial counts in the peripheral blood [18]. In our study,
neither Masp2 deficiency nor MASP-2 antibody treatment
influenced bacterial counts in the blood or brain, and the
effect on disease severity seemed to be driven by a de-
creased inflammatory response. In pneumococcal menin-
gitis, complement activation, notably in the final common
pathway, has previously been found to cause brain damage
and was associated with an adverse outcome [11, 25].
Reduction of complement activation in C3-deficient mice
resulted in less intracranial complications in pneumococ-
cal meningitis, but the lack of C3-mediated opsonophago-
cytosis led to decreased bacterial clearance and worsened
outcome [26]. We hypothesize that in case of Masp2 defi-
ciency, C3b, formed via the classical or alternative path-
way, is still able to opsonize the bacteria for phagocytosis.
This is supported by similar levels of C5b-9 in brains of
Masp2-deficient and WT mice as an indicator of total
complement activation. MASP-2 antibody-treated mice
had reduced brain levels of C5b-9 compared to saline-
treated infected mice. In our treatment model, the MASP-
2 antibody was given in conjunction with antibiotic ther-
apy, while previous studies were performed without anti-
biotic therapy [18]. Another explanation for the difference
in results between these previous studies and our study is
the difference in pneumococcal serotypes (serotype 2 vs.
3). The binding of M-ficolin, in association with MASP-2,
of S. pneumoniae has been shown to be serotype-specific,
at least for certain pneumococcal serotypes [27]. Other
work showed that binding of S. pneumoniae by lectin
pathway pattern recognition molecules occurs only with a
minority of serotypes and that L-ficolin specifically binds
to capsule constituents [28]. Although we found no dif-
ference in C5b-9 brain levels between Masp2-deficient
and WT mice after infection, Masp2 deficiency was
associated with decreased brain cytokine levels and an
increased survival. We hypothesize that the difference
may be explained by a different pace of complement
activation in Masp2-deficient mice compared to wild-
type mice. Masp2-deficient mice could reach a full acti-
vation state of the complement system at a later time
point, which would explain the decreased inflammatory
response and increased survival.
Adjunctive treatment with MASP-2 antibodies re-
sulted in a reduction of disease severity and tended to
reduce mortality despite having no effect on either bac-
terial outgrowth in the CSF and blood or antibiotic-
induced bacterial killing in experimental pneumococcal
meningitis. In our treatment model, we observed noeffect on brain cytokine levels, but there was an effect
on total C5b-9 brain levels. The protective effect holds
promise for future treatment of patients with pneumococ-
cal meningitis, but the effect size seemed to be smaller
than previously observed for adjunctive treatment with
anti-C5 antibodies [13, 16]. However, experiments using
adjunctive treatment with anti-C5 antibodies were per-
formed in a model of pneumococcal meningitis with high
disease severity, with a mortality rate of 100% in the
placebo group [16]. C1 inhibitors have been shown to re-
duce clinical severity, increase bacterial clearance, and
decrease CSF and meningeal inflammation in a rat model
of pneumococcal meningitis [29]. Altogether, these studies
suggest that inhibition of complement activation may be
beneficial in pneumococcal meningitis.
Genetic variations in the Masp2 gene did not explain
inter-individual differences in disease course. However,
this does not negate the importance of MASP-2 in acti-
vation of complement in pneumococcal meningitis.
Involvement of the lectin pathway in invasive pneumo-
coccal disease has been shown by genetic association
studies on mannose-binding lectin (MBL)2 deficiency [7].
In a prospective genetic association study, including 299
patients with pneumococcal meningitis and 216 controls,
we previously showed that the risk for contracting
pneumococcal meningitis was substantially increased for
white individuals homozygous with the defective MBL2 0/
0 genotype (odds ratio 8.21, 95% confidence interval 1.05–
64.1; P = 0.017) [30]. CSF MBL levels were significantly
lower in patients with the A/0 and 0/0 genotype com-
pared to homozygotes with the wild-type alleles (A/A;
P < 0.001). CSF MBL levels were positively correlated
with C3a and iC3b levels, indicating complement acti-
vation by the lectin pathway.
Our study has several limitations. First, selection bias
could have been introduced since CSF was only available
in a portion of patients included in the cohort. However,
patients with and without CSF available had similar
baseline and clinical characteristics, and therefore, selec-
tion bias is unlikely. Second, our analysis of CSF MASP-
2 levels and disease severity is associative and cannot be
seen as proof of causation. Third, we did not backcross
the mice knockout and wild-type strains because of time
and cost considerations. Although the animals are from
the same genetic background (C57/BL6N), they were
not identical except for the Masp2 gene. This means we
cannot rule out that an unidentified small variation
between strains may contribute to the identified pheno-
type. However, this does not influence the CSF and
antibody treatment studies, suggesting a similar role of
MASP2 as established in the knockout experiments.
Fourth, our animal experiments were not performed in
a blinded and randomized manner, which may lead to
an overestimation of the treatment effect. Although
Kasanmoentalib et al. Journal of Neuroinflammation  (2017) 14:2 Page 9 of 10parameters of inflammation and outcome seem to be con-
sistent, this is not according to current standards [31].
Then, randomized controlled experimental trials are
needed comparing adjunctive treatment with MASP-2
antibodies, with and without adjunctive dexamethasone
therapy. Such experimental trials should be adequately
powered to detect differences in mortality, done with
meningitis caused by different serotypes, and ideally be
performed in different experimental laboratories.
Conclusions
Our study stresses the important role of MASP-2 in
pneumococcal meningitis and suggests that MASP-2 in-
hibitory antibodies can attenuate the harmful inflammatory
response during pneumococcal meningitis. Eventually,
anti-MASP-2 antibodies may be used for complement
inhibition in patients as currently these are studies used in
clinical trials (ClinicalTrials.gov Identifier NCT02222545).
Although further experimental proof is needed to confirm
our results, our results present a promising target for
future treatment of pneumococcal meningitis.
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